Stock events for Talphera, Inc. (TLPH)
In September 2025, Talphera announced a private placement financing led by CorMedix Inc. In October 2025, Joseph Todisco from CorMedix was appointed to Talphera's board. In November 2025, the company announced its Third Quarter 2025 Financial Results. In December 2025, an insider increased their holding in the company. In February 2026, insiders purchased shares, the price target was decreased, and quarterly earnings were projected. In March 2026, Talphera announced a 50% enrollment milestone in its NEPHRO-CRRT Registrational Trial. As of March 3, 2026, the stock price was $0.90 per share, reflecting a 66.12% increase from the previous year.
Demand Seasonality affecting Talphera, Inc.’s stock price
Information specifically regarding the demand seasonality for Talphera, Inc.'s products and services is not available.
Overview of Talphera, Inc.’s business
Talphera, Inc. specializes in therapies for medically supervised environments, with primary product candidates including Niyad and LTX-608, along with Fedsyra and phenylephrine product candidates. The company also has an FDA-approved product, DSUVIA, for acute pain management. Talphera changed its name from AcelRx Pharmaceuticals, Inc. in January 2024.
TLPH’s Geographic footprint
Talphera, Inc. is headquartered in San Mateo, California, United States. While its stock is listed on NasdaqCM in the US and on the Deutsche Boerse AG in Germany, its primary operational and commercialization focus is centered in the United States.
TLPH Corporate Image Assessment
Talphera, Inc.'s brand reputation was impacted by its rebranding in January 2024, changing its name from AcelRx Pharmaceuticals, Inc. to Talphera, Inc. This move aimed to distance the company from its historical association with opioid-based pain management and highlight its expanded pipeline.
Ownership
Talphera, Inc. has a diverse ownership structure, including institutional owners, insiders, and retail investors. There are 41 institutional owners and shareholders holding approximately 30.71% to 44.78% of the company's stock. Insiders hold approximately 5.70% of the stock. Retail investors hold a significant portion, estimated to be around 61.90%.
